Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| TriSalus Life Sciences Inc | TLSI | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 9.68 | 03:09:43 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.68 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 3.32 - 16.24 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 9.68 | USD |
TriSalus Life Sciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 262.90M | - | - | - | -6.68 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
TriSalus Life Sciences News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TLSI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.50 | 10.17 | 9.30 | 9.85 | 10,084 | 0.18 | 1.89% |
| 1 Month | 10.08 | 10.24 | 9.11 | 9.65 | 48,217 | -0.40 | -3.97% |
| 3 Months | 9.31 | 10.42 | 8.80 | 9.58 | 41,957 | 0.37 | 3.97% |
| 6 Months | 3.71 | 10.42 | 3.33 | 8.31 | 56,024 | 5.97 | 160.92% |
| 1 Year | 13.80 | 16.24 | 3.32 | 7.54 | 51,646 | -4.12 | -29.86% |
| 3 Years | 13.80 | 16.24 | 3.32 | 7.54 | 51,646 | -4.12 | -29.86% |
| 5 Years | 13.80 | 16.24 | 3.32 | 7.54 | 51,646 | -4.12 | -29.86% |
TriSalus Life Sciences Description
| TriSalus Life Sciences was created to develop and commercialize an innovative approach for the treatment of liver and pancreatic tumors. Our platform approach addresses immune dysfunction in liver and pancreatic tumors by combining immunotherapy drugs with highly effective drug delivery technology. Our companyâ¿¿s heritage is in the development of devices for our Pressure-Enabled Drug Deliveryâ¿¢ (PEDDâ¿¢) method. Building on this history, we launched our new platform in 2020 with the acquisition of SD-101. SD-101 is an investigational toll-like receptor 9 (TLR9) agonist with the potential to modulate the immune system to enable immunotherapy. |
